Menu
Cart 0

Clive Bates publishes new Q&A on nicotine science and policy

Posted by Carlee Fero on

Clive Bates, one of the foremost experts on vaping and scrutiny of current tobacco control policies and research has published a new Q&A to address many of the myths and speculations currently creating the narrative on the vaping/ecigarette industry.

Link to this article here:
https://www.clivebates.com/new-nicotine-science-and-policy-q-a-published/



New nicotine science and policy Q & A published

I have just published a new question and answer (Q & A) resource on nicotine science and policy.  It is available as a page accessible from the top menu of this blog and also at this address: Nicotine science and policy Q & A.  I am hoping to keep it up to date… the questions as they stand at present are as below.  My answers are on the Q & A page above – please visit, leave comments, suggestions for other questions, better answers or further reading.

The questions

1. Strategy – what is the purpose of tobacco and nicotine policy?
1.1 What are the goals of tobacco and nicotine policy?
1.2 What is ‘tobacco harm reduction’?
1.3 What products are involved?
1.4 Shouldn’t we aim for a nicotine-free society?
1.5 What is the ‘endgame’ for tobacco?

2. Safety and relative risk – what are the risks?
2.1 Are e-cigarettes less harmful than cigarettes?
2.2 Do the recent US cases of severe lung injury prove that e-cigarettes are very harmful?
2.3 What about long term effects – shouldn’t we take a precautionary approach?
2.4 It took decades for the harmful effects of smoking to emerge, won’t it be the same with vaping?
2.5 How much less harmful are e-cigarettes than cigarettes?
2.6 Is it fair to say e-cigarettes are likely to be at least 95% lower risk than smoking?
2.7 Do people understand the risks of vaping?
2.8 Isn’t this just the ‘light cigarette’ tobacco industry scam all over again?

3. Quitting smoking – do vaping products displace smoking?
3.1 Do e-cigarettes help people quit smoking?
3.2 Isn’t most vaping ‘dual-use’ of e-cigs and cigarettes?
3.3 What is the difference between NRTs, smoking cessation pharmaceuticals and vape products?
3.4 Should the healthcare system cover e-cigarettes as smoking cessation aids?
3.5 What about people who are disadvantaged and cannot afford to vape? Should they get support?
3.6 Should the healthcare system help vapers to go nicotine-free and quit vaping?

4. Youth – how should we address the uptake of adult products by young people
4.1 Why do e-cigarettes appeal to adolescents?
4.2 Is there a ‘youth vaping epidemic’ in the United States?
4.3 Is vaping a gateway to smoking?
4.4 Should flavours be banned to stop youth vaping?
4.5 Should e-cigarette sales be restricted to people aged 18 and over?
4.6 Does nicotine damage the developing adolescent brain?
4.7 What can be done to protect young people?

5. Regulation – how should governments handle reduced risk products?
5.1 Should e-cigarettes be banned?
5.2 Should e-cigarettes be regulated like cigarettes?
5.3 Should e-cigarettes be regulated as smoking cessation medicines with pharmaceutical regulation?
5.4 What is the right approach to regulating e-cigarettes?
5.5 What are the potential unintended consequences of vaping regulation?
5.6 Should different categories of vapour products like THC or nicotine salts be regulated in different ways?
5.7 Should regulators impose limits on the strength of nicotine in e-liquids?
5.8 Why does Juul use a high strength nicotine liquid in the US?
5.9 Should there be a special tax on e-cigarettes?
5.10 Does tobacco harm reduction undermine tobacco control?

6. Vaping in public places – should it be permitted and who should decide?
6.1 Do e-cigarette vapours pose the same risks to bystanders as second-hand smoke from cigarettes?
6.2 Should vaping be banned by law in public places and workplaces?

7. Marketing – what marketing freedoms or constraints are appropriate?
7.1 Are vaping products aggressively marketed to teens?
7.2 Should advertising for reduced-risk products be banned?
7.3 How to maximise the benefit to smokers and would-be smokers, while minimising recruitment of non-users?

8. Retailing – who should sell and under what conditions?
8.1 Where should e-cigarettes and other reduced-risk products be sold and not sold?
8.2 Should e-cigarettes be available only through pharmacies or on prescription or over-the-counter everywhere?
8.3 Should vaping products be available on-line?

9. Tobacco industry – pariahs, predators or player?
9.1 Are e-cigarettes a tobacco industry ploy to keep people smoking?
9.2 Should tobacco control authorities collaborate with tobacco-related industries in pursuit of public health objectives?
9.3 If tobacco companies want to reduce the harm caused by cigarettes, why don’t they just stop selling cigarettes?

10. Rapid responses to the biggest myths about vaping
[14 additional rapid-fire questions]

Postscript. Vaping – what people are getting wrong. The Economist


Share this post



← Older Post